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ABSTRACT 
Objectives: although melatonin prescribing in England has been increasing in recent 
years there have been no large scale studies on the safety of melatonin compared to 
other medical treatments for insomnia. The primary aim of this study was to examine 
the association between exposure to melatonin, hypnotic benzodiazepines 
(temazepam, nitrazepam) or Z-drugs (zolpidem, zopiclone) and fracture risk.  
Design:  retrospective cohort study  
Setting:  309 general practices contributing to the Health Improvement Network 
(THIN) between 2008 and 2013. 
Participants: 1,377 patients aged 45 years and older prescribed melatonin; 880 
patients prescribed hypnotic benzodiazepines; 1,148 patients prescribed Z-drugs 
and 2,752 unexposed controls matched by age, gender and practice. 
Main outcome: fracture following prescription of study drugs ascertained from 
practice records. 
Results: the unadjusted hazard ratios for fracture during the follow-up period were 
1.90 (95% CI 1.41-2.57) for melatonin, 1.70 (95% CI 1.18-2.46) for hypnotic 
benzodiazepines and 2.03 (95% CI 1.45-2.84) for Z-drugs. After adjustment for 26 
covariates, the hazard ratios were 1.44 (95% CI 1.01-2.04) for melatonin, 1.26 (95% 
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CI 0.82-1.92) for hypnotic benzodiazepines and 1.52 (95% CI 1.04-2.23) for Z-drugs. 
Only patients with three or more melatonin prescriptions had elevated risk. The 
mean time to fracture was 1.04 years and there was no significant different in mean 
time to fracture between the cohorts. 
Conclusions: In this large cohort of patients attending UK primary care, melatonin 
and Z-drugs were associated with a significantly increased risk of fracture. With the 
use of melatonin increasing steadily over time, this study adds to the literature on the 
safety profile of this drug.  
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Introduction 
Medicines used to treat insomnia include hypnotic benzodiazepines, non-
benzodiazepine sedatives (Z-drugs) and melatonin agonists [1,2]. These drugs are 
licensed on the basis that they are effective with regard to sleep parameters [3].  
However, older people have an increased risk of hip fracture associated with 
anxiolytic or hypnotic drug use including short acting benzodiazepine anxiolytics and 
Z-drugs [4]. Psychotropic drugs including anxiolytics and hypnotics are reported to 
increase the risk of falling [5] while zolpidem is associated with fractures requiring 
hospitalization [6]. Falls and fractures are a major health issue for older adults. One 
study reported that “more than 30% of people over 65 years of age fall each year 
and in half of the cases falls are recurrent” [7]. Drugs that increase the propensity to 
fall are therefore a cause for concern. The literature does not appear to contain any 
studies assessing the risk of fracture associated with the use of melatonin. 
 
Prolonged-release (PR) melatonin has been shown to reduce sleep onset latency 
and increase subjective sleep quality in two large trials in patients over 55 years and 
has no known motor side effects [3]. Another review of PR-melatonin noted that, 
while evidence was based on three randomised, placebo-controlled trials, the 
outcomes are highly subjective [8].  Whilst data on the efficacy and safety of 
melatonin were satisfactory [9,10,11,12] for the granting of a marketing authorisation 
in 2008 there is little detailed information on the safety of melatonin. In 2014 there 
were 491,000 prescriptions for melatonin in England compared to 262,000 in 2011.  
Melatonin prescriptions accounted for 5% of total hypnotic scripts in England 
compared to 2.5% in 2011 [13]. Over the 10 years between 2004 and 2014, 
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melatonin prescribing increased by 21% [14]. The reason for this increase is 
probably because of the safety concerns over sedative hypnotics and Z-drugs[15]. 
 
One meta-analysis concluded that melatonin has a “relatively benign” side effect 
profile [16]. Melatonin has also been assessed as having “no-reported side effects” 
[17]. Reported benefits of melatonin include cerebroprotective and anticancer 
properties [14] and improved bone biomechanical competence [18]. However other 
“scientific pre-clinical studies” suggest that the “pharmacological profile of melatonin 
constitutes…. a basis for prediction of adverse drug reactions or side effects” [19]. 
Drowsiness is a reported side effect in studies of human subjects given melatonin 
[20,21]. The current study cannot, however, provide the data for evaluating the 
pharmacological profile of melatonin or the mechanism that is responsible for 
increased fracture risk. 
 
Given concerns about adverse events associated with hypnotic drug use and the 
lack of information about melatonin, the aim of this study is to assess the fracture 
risk of melatonin and hypnotic drugs among older adults.  
 
Methods 
 
Data Source 
The data for this study were obtained from The Health Improvement Network-THIN 
[22]. THIN is a database of electronic medical records from over 1500 GPs in over 
380 UK practices.  
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Participants 
Melatonin is licensed in the UK for patients aged 55 or over for a short period of time 
(up to 13 weeks) [23].However as the objective was to assess the fracture risk of 
melatonin and hypnotic drugs among older adults we extended the age range. 
Capturing data from the age of 45 and above may also reflect “real life” use of the 
drug. Full details of study participants may be found in the on-line appendix.  
 
Cohort 1 comprised patients who were 45 years and older when they were first 
prescribed melatonin (BNF 4.1.1; melatonin) between 01/07/2008 and 30/06/2013.  
Cohort 2A comprised patients who received at least 2 prescriptions of hypnotic 
benzodiazepines (BNF 4.1.1; temazepam, nitrazepam) between 01/07/2008 and 
30/06/2013 and whose electronic record contained no prescriptions for melatonin.  
 
Cohort 2B comprised patients prescribed at least 2 prescriptions of Z-drugs (BNF 
4.1.1; zolpidem and zopiclone) between 01/07/2008 and 30/06/2013 and whose 
electronic record contained no prescriptions for melatonin.  
 
Cohort 3 comprised patients who had never been prescribed melatonin or hypnotic 
benzodiazepines or Z-drugs, and who met the matching criteria. Their observation 
period began on the date of the first melatonin prescription for the Cohort 1 member 
to whom they were matched. 
 
The initial aim was to have 1:1:1 matching for cohorts 1, 2a and 2b, and 1:2 
matching for cohorts 1 and 3. However, due to the matching and exclusion criteria it 
was not possible to achieve these ratios. The final achieved cohorts were: melatonin 
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(N=1,377), hypnotic benzodiazepines (N=880), Z-drugs (N=1,148) and controls 
(N=2,752). Cohort members were recruited from 309 practices. 
 
Study outcome was any fracture following study entry. The reason for selecting all 
fractures was because of various mechanisms cited in the literature that could result 
in a fracture [4]. Since, as noted above, this study is not evaluating the mechanism 
that may lead to fracture, it was decided not to exclude particular kinds of fracture. 
Fracture was therefore defined by a comprehensive list of READ codes [24](See 
Supplementary data, available at Age and Ageing online for frequency of fracture 
codes). 
 
Each case was followed from study entry date to date of first fracture or censorship 
(i.e. the patient leaves the practice for any reason) or the end of the observation 
period [30-05-2013]). 
 
Covariates and potential confounders 
Potential confounders were: gender, age at study entry, medical morbidity, 
prescriptions for non-study drugs, Body Mass Index (BMI), Townsend quintile score 
(a measure of material deprivation), smoking and alcohol status.  Smoking and 
alcohol use were recorded within the dataset as current, previous or never.  
 
Medical morbidity was ascertained using READ codes for arthritis, anxiety, asthma, 
dementia/Alzheimer’s disease, cancer, COPD, diabetes, gastrointestinal disorders, 
epilepsy, hypertension, ischaemic heart disease, musculoskeletal conditions, 
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psychiatric conditions (excluding anxiety) stroke, sleep disorders, ophthalmic 
disorders and pre-study fractures. 
 
As with similar studies [25], the observation period for the ascertainment of 
covariates was the entire interval for which data are available for a patient between 
the time their record starts (prior to recruitment) and either the end of the study 
period, censorship or death. 
 
Analysis 
Hazard ratios for fracture following recruitment into the study (defined as the first 
prescription of a study drug) were estimated using Cox proportional hazards models. 
Two models were run. The first model was unadjusted for any covariate while the 
second was adjusted for the 26 covariates described above. 
 
Results 
Crude fracture rates over the study period were 6.0% for melatonin, 5.8% for 
hypnotic benzodiazepines, 5.9% for Z-drugs and 3.2% controls. The average age at 
study entry was 64.7 (SD=11.6). Average exposure time (i.e. from study entry to end 
of follow up) was 2.6 years (SD=1.2 years) There were no significant differences 
between the cohorts in terms of age or exposure time. Average time to fracture was 
1.04 years. There was no significant different in average time to fracture between the 
cohorts. 
 
Table 1 shows that compared to the hypnotic benzodiazepines and Z-drug cohorts, 
the melatonin cohort had a higher rate of sleep disorders, dementia/Alzheimer’s 
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disease, a lower rate of cancer and fewer lifetime prescriptions for all drugs. Pre-
study facture rates and musculoskeletal problems were similar across these cohorts. 
Table 1 also shows that compared to the control cohort, the melatonin cohort had 
higher rates of anxiety, arthritis, asthma, cancer, CHD, COPD, diabetes, 
musculoskeletal problems, psychiatric disorders, sleep disorders and stroke. 
 
[Table 1 about here] 
 
Table 2 shows the unadjusted and adjusted hazard ratios for the study cohorts. 
There was a downward adjustment after controlling for comorbidity. Thus some of 
the effect attributed to cohort membership is accounted for by comorbidity. However, 
hazard ratios for associations between melatonin, Z-drugs and fractures remained 
statistically significant after adjustment. 
 
71% of melatonin prescriptions for the prolonged release formulation, while 29% 
were for immediate release formulation. 79% of those prescribed melatonin were 
prescribed the drug once or twice, while 21% were prescribed three times or more. 
Among the latter group, the average number of prescriptions was 11.9. Only those 
with three or more melatonin prescriptions had elevated risk (data are not shown in 
the paper). 
 
[Table 2 about here] 
 
Table 3 shows that predictors of higher rates of post study fracture were: 
dementia/Alzheimer’s disease, musculoskeletal problems, pre-study fracture and 
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lifetime receipt of more than 501 prescriptions. The only predictor of a lower rate of 
post study fracture was being overweight. 
 
Table 3 about here 
 
Discussion 
The main finding of this study is that both Z-drugs and melatonin were found to be 
independently associated with increased fracture risk. One of the strengths of this 
study was the inclusion of a large number of covariates that potentially might have 
explained the hazards associated with these drugs. 
 
Only for hypnotic benzodiazepines did the inclusion of covariates result in a 
downward adjustment that resulted in a non-significant hazard ratio. However the 
size of this cohort was considerably smaller than the other drug cohorts so this may 
be an indicator of statistical power. 
 
As noted in the introduction, there were reasons to indicate that melatonin might be 
safer than the hypnotic drugs, although other studies indicated that there could be 
adverse events[16]. As this study only shows an increased risk for the large 
diagnostic category of “fracture”, further work could explore if the study drugs are 
associated with particular types of fracture that occur as a result of falling (e.g. hip 
fractures), which in turn may be caused by specific risk factors such as drowsiness 
[16]. Furthermore this study did not examine if there was a dose-response 
relationship between the study drugs and fracture risk. In the case of melatonin, the 
risk was only observed for those prescribed the drug three or more times. 
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This study supports the growing evidence that Z-drugs are not safer than 
benzodiazepines with respect to the risk of fracture [26,27]. Given the caution now 
attached to the prescribing of hypnotic drugs, this study may indicate that similar 
considerations should be attached to melatonin. 
 
Strengths and limitations of the study should be noted. The THIN data set provided 
large cohorts of patients prescribed melatonin, together with matched controls 
receiving hypnotic benzodiazepines and Z-drugs and controls receiving neither 
melatonin nor hypnotic drugs. Exposure was based on prescription recorded by 
General Practitioners rather than self-report. The study was able to control for a wide 
range of potential confounders and several possible explanations were considered, 
e.g. that the risk of fractures could be attributed to ophthalmic disorders or musculo-
skeletal conditions.. The study also controlled for sleep disorders and these were not 
significantly associated with fracture. The length of follow-up was a further strength 
of this study as few of the earlier studies of melatonin have looked at a time frame of 
over 2 years following receipt of the drug. The main limitation of this study is that the 
design was non-randomised. It is impossible to exclude confounding arising from 
unmeasured factors, or measurement error [28]. The study controls for the presence 
of medical conditions but not their severity. 
 
In conclusion, prescriptions for melatonin and hypnotic drugs were associated with 
significantly increased risk of fracture over a two-year period after adjusting for a 
range of potential confounders. The study design has a number of strengths which 
suggest that these findings are robust but we also note important limitations.  
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Key points 
 
 In this large cohort of patients attending UK primary care, melatonin and Z-drugs 
were associated with a significantly increased risk of fracture over a two year 
period. 
 This study controlled for a wide range of potential confounders including sleep 
disorders, musculoskeletal and ophthalmic conditions. 
 With the use of melatonin increasing steadily over time in the UK, this study adds 
to the small literature on the safety profile of this drug. 
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Table 1. Prevalence (%) of covariates for all study cohorts. 
  
Prevalence (Full 
Medical Record) 
Study Cohorts 
Covariate Prevalence (%) 
Melatonin 
(N=1,371) 
Hypnotic 
benzodiazepines 
(N=880)  
Z-drugs 
(N=1,148) 
Controls 
(N=2,751) 
1 Anxiety disorder 30.2 32.4 33.6 12.5 
2 Arthritis  31.8 32.5 29.9 24.0 
3 Asthma 17.9 16.2 15.3 10.1 
4 Cancer 23.3 32.4 29.6 19.5 
5 
Coronary Heart 
Disease (CHD) 
17.2 18.6 17.7 9.3 
6 
Chronic 
Obstructive 
Pulmonary 
Disease (COPD) 
14.2 15.4 13.2 9.3 
7 Diabetes 14.5 12.9 14.5 11.6 
8 
Dementia/ 
Alzheimer’s 
disease 
7.4 4.1 5.0 3.0 
9 Epilepsy 3.8 4.3 3.4 2.1 
10 
Gastrointestinal 
disorder 
2.3 2.4 2.3 1.5 
11 Hypertension 36.1 37.4 38.4 36.5 
12 
Ischaemic heart 
disease  
17.2 18.6 18.4 13.5 
13 
Musculoskeletal 
problems 
89.6 89.4 86.5 77.4 
14 
Psychiatric 
diagnoses 
(excluding 
anxiety) 
46.9 49.3 47.6 20.7 
15 Sleep disorder 25.7 18.9 16.5 2.5 
16 Stroke 9.2 8.9 7.8 5.7 
17 
Ophthalmic 
Conditions 
23.9 23.7 22.3 19.5 
18 
Fracture pre-
study 
24.7 24.6 26.9 21.3 
19 
Smoking Status 
(% current) 
20.7 26.4 27.1 17.3 
20 
Alcohol Status 
(% current) 
68.4 67.5 66.5 70.1 
21 
Number of 
prescriptions (all 
drugs) 
[MEAN/SD] 
486 [530] 542 [772] 503 [636] 409 [561] 
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Table 2. Unadjusted and adjusted cohort hazard ratios for post-study entry 
fracture 
      Unadjusted Adjusted 
      
Hazard 
Ratio 
95.0% CI for 
Hazard Ratio 
Sig. 
Level 
Hazard 
Ratio 
95% C.I. for 
Hazard Ratio 
Sig. 
Level 
Cohort 
N 
cases 
N 
controls 
  Lower Upper 
 p-
value 
  Lower Upper 
 p-
value 
Controls     1       1       
Melatonin 1377 2752 1.90 1.41 2.57 <0.001 1.44 1.01 2.04 0.04 
Hypnotic 
benzodiazepi
nes 880 1759 
1.70 1.18 2.46 <0.001 1.26 0.82 1.92 0.29 
Z-drugs  1148 2294 2.03 1.45 2.84 <0.001 1.52 1.04 2.23 0.03 
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Table 3. Adjusted covariate hazard ratios for post-study entry fracture 
 
   N 
Hazard 
Ratio 95% C.I. for Hazard Ratio 
Sig. 
Level 
      Lower Upper  p-value 
Anxiety disorder 1440 1.04 0.8 1.37 0.76 
Arthritis 1738 0.97 0.75 1.25 0.8 
Asthma 847 1.29 0.95 1.76 0.1 
Cancer 1490 1.07 0.82 1.4 0.63 
Coronary Heart Disease (CHD) 864 0.75 0.46 1.24 0.26 
Chronic Obstructive Pulmonary Disease (COPD) 741 1.1 0.76 1.59 0.62 
Diabetes 801 1.24 0.87 1.77 0.23 
Dementia   255 1.55 0.95 2.53 0.08 
Epilepsy 190 0.92 0.48 1.75 0.79 
Gastrointestinal disorder 120 0.87 0.38 1.98 0.74 
Hypertension 2284 0.9 0.69 1.18 0.45 
Ischaemic heart disease 988 1.08 0.68 1.72 0.75 
Musculoskeletal problems 5170 1.97 1.19 3.26 0.01 
Other psychiatric diagnoses 2210 0.96 0.74 1.25 0.78 
Sleep disorder 784 1.14 0.83 1.55 0.42 
Stroke 455 1 0.65 1.53 0.99 
Ophthalmic Disorders 859 1.23 0.93 1.62 0.14 
Fracture pre-study 1460 1.72 1.35 2.2 <.01 
Number of Prescriptions (all drugs); 1-99; 
reference category: 1847 1       
100-300 1740 1.15 0.79 1.68 0.48 
301-500 925 1.22 0.79 1.9 0.37 
501+ 1675 1.62 1.07 2.46 0.02 
Body Mass Index; “healthy” BMI [18-24.9]; 
reference category: 1766 1       
underweight [10-18.4] 172 1.49 0.88 2.53 0.14 
overweight [25-29.9] 2134 0.62 0.46 0.83 <.01 
obese [30+] 1597 0.72 0.52 1 0.05 
Alcohol;  lifelong teetotal; reference category 1136 1       
current drinker 4248 1.22 0.9 1.66 0.2 
ex-drinker 233 1.44 0.8 2.58 0.22 
Smoking; lifelong non-smoker; reference category 3149 1       
current smoker 1312 1.01 0.72 1.4 0.97 
ex-smoker 1666 1.04 0.78 1.38 0.81 
Townsend score; most deprived quintile; reference 
category 1592 1       
2nd most deprived quintile 1378 0.93 0.66 1.32 0.7 
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middle quintile 1144 0.81 0.55 1.19 0.29 
2nd most affluent quintile 964 1.28 0.9 1.82 0.17 
most affluent quintile 905 0.96 0.65 1.43 0.85 
Gender, Male; reference category 2518         
Gender, Female 3669 2.15 1.61 2.87 <.01 
Age:45-54; reference category 1451         
Age:55-64 1976 1.02 0.73 1.44 0.89 
65-74 1475 0.91 0.62 1.36 0.66 
75+ 1285 1.33 0.87 2.05 0.19 
 
